Sandra M. Swain
#36,185
Most Influential Person Now
American oncologist
Sandra M. Swain's AcademicInfluence.com Rankings
Sandra M. Swainphilosophy Degrees
Philosophy
#6405
World Rank
#9439
Historical Rank
Logic
#3579
World Rank
#4766
Historical Rank
Download Badge
Philosophy
Sandra M. Swain's Degrees
- Bachelors Biology University of Texas at Austin
Similar Degrees You Can Earn
Why Is Sandra M. Swain Influential?
(Suggest an Edit or Addition)According to Wikipedia, Sandra M. Swain is an American oncologist, breast cancer specialist and clinical translational researcher. She is currently a professor of Medicine at the Georgetown University School of Medicine and the Associate Dean for Research Development at Georgetown University Medical Center and MedStar Health as well as an adjunct professor of Medicine at the F. Edward Hébert School of Medicine of the Uniformed Services University of Health Sciences. She is also a past President of the American Society of Clinical Oncology , serving from 2012 through 2013.
Sandra M. Swain's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. (2005) (5306)
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis (2014) (2895)
- Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. (2012) (1765)
- Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. (2015) (1516)
- Congestive heart failure in patients treated with doxorubicin (2003) (1516)
- Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 (2009) (1111)
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. (2013) (857)
- Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. (2005) (776)
- Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. (2014) (741)
- Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. (2011) (680)
- Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials (2018) (614)
- Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. (1997) (559)
- Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials (2015) (550)
- Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. (2003) (548)
- Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. (2006) (514)
- Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials. (2017) (473)
- Peripheral neuropathy induced by microtubule-stabilizing agents. (2006) (450)
- International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. (2011) (439)
- Bevacizumab added to neoadjuvant chemotherapy for breast cancer. (2012) (432)
- Ductal carcinoma in situ, complexities and challenges. (2004) (397)
- Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. (2013) (327)
- Mastectomy versus breast-conserving therapy in the treatment of stage I and II carcinoma of the breast: a randomized trial at the National Cancer Institute. (1992) (326)
- Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. (2006) (319)
- Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. (2010) (305)
- Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems (2008) (298)
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. (2020) (287)
- Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer (2012) (284)
- Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. (1987) (275)
- Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. (2014) (274)
- Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. (1989) (248)
- Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. (1997) (240)
- Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. (2005) (224)
- Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. (2017) (215)
- Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. (2012) (200)
- Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials (2019) (197)
- Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). (2017) (196)
- Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. (2004) (184)
- Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. (2004) (181)
- Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA (2014) (179)
- Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. (2007) (176)
- Autocrine and paracrine growth regulation of human breast cancer. (1986) (169)
- Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. (2012) (166)
- Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. (2013) (144)
- Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management. (2008) (144)
- NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2. (2019) (141)
- Cardiac Toxicity and Efficacy of Trastuzumab Combined with Pertuzumab in Patients with Trastuzumab-Insensitive Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer (2008) (140)
- CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer. (2010) (136)
- Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. (2008) (134)
- Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. (2002) (131)
- Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. (2015) (131)
- Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study (2017) (127)
- Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. (2011) (122)
- Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. (2013) (121)
- Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial. (2015) (107)
- Luminal A Breast Cancer and Molecular Assays: A Review. (2018) (106)
- Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial (2008) (104)
- Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. (2013) (101)
- Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC) (2012) (99)
- Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. (2004) (99)
- Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study (2019) (94)
- The influence of a Gene expression profile on breast cancer decisions (2008) (91)
- The effect of systemic therapy on local-regional control in locally advanced breast cancer. (1992) (89)
- Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer (2010) (87)
- Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer. (2002) (87)
- Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials (2021) (81)
- Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2–Positive Breast Cancer: Analysis of the NSABP B-31 Trial (2017) (81)
- Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)->paclitaxel (T) vs. AC->T with trastuzumab (H) (2006) (81)
- Abstract S1-03: Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer (2013) (79)
- Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. (2019) (74)
- Results of the National Cancer Institute early breast cancer trial. (1992) (73)
- Patient Navigation Significantly Reduces Delays in Breast Cancer Diagnosis in the District of Columbia (2012) (73)
- Influence of Garlic (Allium sativum) on the Pharmacokinetics of Docetaxel (2006) (72)
- The effects of hormonal and chemotherapy on tumoral and nonneoplastic breast tissue. (1990) (71)
- Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30 (2018) (71)
- Phase I Trial of the Cyclin-Dependent Kinase Inhibitor Flavopiridol in Combination with Docetaxel in Patients with Metastatic Breast Cancer (2004) (69)
- Twenty-five year results of the national cancer institute randomized breast conservation trial (2012) (69)
- HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now (2021) (68)
- Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR). (2005) (68)
- Locally advanced and inflammatory breast cancer. (2008) (67)
- Expression levels of eIF4E, VEGF, and cyclin D1, and correlation of eIF4E with VEGF and cyclin D1 in multi-tumor tissue microarray. (2007) (66)
- Amenorrhea from breast cancer therapy--not a matter of dose. (2010) (66)
- Heterogeneous expression of erbB-2 messenger RNA in human breast cancer. (1989) (66)
- Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. (2013) (66)
- Abstract S5-1: Biomarker analyses in CLEOPATRA: A phase III, placebo-controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC) (2012) (66)
- Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA) (2013) (65)
- Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab--initial experience. (2007) (61)
- Clinical aspects of inflammatory breast cancer. (2005) (61)
- Ongoing adjuvant trials with trastuzumab in breast cancer. (2003) (61)
- Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer. (2010) (60)
- Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer (2020) (60)
- The Epothilones: Translating from the Laboratory to the Clinic (2008) (60)
- Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA. (2014) (58)
- Treatment of estrogen deficiency symptoms in women surviving breast cancer. The Hormone Foundation, Canadian Breast Cancer Research Initiative, National Cancer Institute of Canada, Endocrine Society, and the University of Virginia Cancer Center and Woman's Place. (1999) (54)
- Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group (2020) (54)
- Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41. (2012) (52)
- Changes in neurologic function tests may predict neurotoxicity caused by ixabepilone. (2006) (51)
- Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies (2013) (51)
- Therapeutic Strategies for Triple-Negative Breast Cancer (2008) (51)
- Adult multicenter trials using dexrazoxane to protect against cardiac toxicity. (1998) (51)
- IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer. (2019) (50)
- NCCAM/NCI Phase 1 Study of Mistletoe Extract and Gemcitabine in Patients with Advanced Solid Tumors (2010) (48)
- Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer (2006) (47)
- Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor. (2003) (47)
- Abstract S5-5: Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: Final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831 (2012) (46)
- A phase II trial with trastuzumab and pertuzumab in patients with HER2-overexpressed locally advanced and metastatic breast cancer. (2006) (46)
- Effect of preoperative chemotherapy on mastectomy for locally advanced breast cancer. (1990) (45)
- ASCO's approach to a learning health care system in oncology. (2013) (45)
- Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs (2018) (45)
- Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer (2014) (43)
- CDK4/6 inhibitors in breast cancer therapy: Current practice and future opportunities (2018) (43)
- Gene Expression Profile and Angiogenic Markers Correlate with Response to Neoadjuvant Bevacizumab Followed by Bevacizumab plus Chemotherapy in Breast Cancer (2008) (42)
- Abstract S1-11: Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC) (2012) (42)
- Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer. (2005) (40)
- Tamoxifen for patients with estrogen receptor-negative breast cancer. (2001) (39)
- Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials (2022) (39)
- Autocrine and paracrine growth regulation of human breast cancer (1986) (39)
- Circulating biomarkers of bevacizumab activity in patients with breast cancer (2008) (39)
- A prospective study of adjuvant CMF in males with node positive breast cancer: 20-year follow-up (2007) (37)
- A Phase II Trial of Neoadjuvant Docetaxel and Capecitabine for Locally Advanced Breast Cancer (2004) (37)
- Abstract S3-06: A phase III trial evaluating pCR in patients with HR+, HER2-positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) +/- estrogen deprivation: NRG Oncology/NSABP B-52 (2017) (37)
- Intensive outpatient adjuvant therapy for breast cancer: results of dose escalation and quality of life. (1996) (36)
- Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38 (2015) (36)
- Update on adjuvant chemotherapy for early breast cancer. (2000) (35)
- Dexrazoxane for reducing anthracycline-related cardiotoxicity in children with cancer: An update of the evidence (2014) (35)
- NSABP B-30: definitive analysis of patient outcome from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer. (2009) (35)
- 350O_PRFINAL OVERALL SURVIVAL (OS) ANALYSIS FROM THE CLEOPATRA STUDY OF FIRST-LINE (1L) PERTUZUMAB (PTZ), TRASTUZUMAB (T), AND DOCETAXEL (D) IN PATIENTS (PTS) WITH HER2-POSITIVE METASTATIC BREAST CANCER (MBC) (2014) (35)
- Review of flavopiridol, a cyclin-dependent kinase inhibitor, as breast cancer therapy. (2002) (32)
- Adjuvant chemotherapy for breast cancer: an update. (2001) (32)
- Increasing the dose density of adjuvant chemotherapy by shortening intervals between courses or by sequential drug administration significantly reduces both disease recurrence and breast cancer mortality: An EBCTCG meta-analysis of 21,000 women in 16 randomised trials (2018) (32)
- Gene Expression Patterns and Profile Changes Pre- and Post-Erlotinib Treatment in Patients with Metastatic Breast Cancer (2005) (32)
- SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function. (2017) (32)
- Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-stage HER2-positive Breast Cancer. (2019) (29)
- A pilot study of a culturally targeted video intervention to increase participation of African American patients in cancer clinical trials. (2012) (29)
- Aromatase inhibitors--a triumph of translational oncology. (2005) (29)
- Preliminary report of the NCI early breast cancer (BC) study: A prospective randomized comparison of lumpectomy (L) and radiation (XRT) to mastectomy (M) for stage I and II BC (1987) (28)
- Detectable inhibition of heparin-binding growth factor activity in sera from patients treated with pentosan polysulfate. (1993) (28)
- Tamoxifen: the long and short of it. (1996) (27)
- Quantitative Gene Expression by Recurrence Score in ER-Positive Breast Cancer, by Age (2015) (27)
- Locoregional recurrence (LRR) after neoadjuvant chemotherapy (NAC): Pooled-analysis results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC). (2014) (26)
- Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx® Digital Spatial Profiler (2021) (26)
- Bevacizumab and heart failure risk in patients with breast cancer: a thorn in the side? (2011) (26)
- The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. (2011) (25)
- A phase II clinical trial of ZD1839 (Iressa™) in combination with docetaxel as first-line treatment in patients with advanced breast cancer (2007) (25)
- Update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)→paclitaxel (T) vs. AC→T with trastuzumab (H). (2006) (25)
- S2-3: NSABP Protocol B-34: A Clinical Trial Comparing Adjuvant Clodronate vs. Placebo in Early Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Tamoxifen or No Therapy – Final Analysis. (2011) (25)
- Phase II study of oral etoposide for patients with advanced breast cancer (1995) (25)
- CA 125 Elevation in Breast Cancer: A Case Report and Review of the Literature (2004) (25)
- Treatment of patients with inflammatory breast cancer. (1989) (25)
- The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer (2014) (25)
- The impact of systemic therapy following ductal carcinoma in situ. (2010) (24)
- Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management. (2022) (24)
- Cardiac dysfunction after cancer treatment. (2011) (23)
- Interim joint analysis of the ABC (anthracyclines in early breast cancer) phase III trials (USOR 06-090, NSABP B-46I/USOR 07132, NSABP B-49 [NRG Oncology]) comparing docetaxel + cyclophosphamide (TC) v anthracycline/taxane-based chemotherapy regimens (TaxAC) in women with high-risk, HER2-negative br (2016) (23)
- Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group. (2011) (22)
- De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry. (2020) (22)
- Selection of therapy for stage III breast cancer. (1990) (22)
- Primary systemic chemotherapy for inflammatory breast cancer (2010) (22)
- Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination (2019) (22)
- What currently defines a breast center? Initial data from the national accreditation program for breast centers. (2013) (22)
- End-of-study analysis from the phase III, randomized, double-blind, placebo (Pla)-controlled CLEOPATRA study of first-line (1L) pertuzumab (P), trastuzumab (H), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC). (2019) (22)
- Absence of pharmacokinetic drug–drug interaction of pertuzumab with trastuzumab and docetaxel (2013) (21)
- Abstract P5-18-26: Confirmatory overall survival (OS) analysis of CLEOPATRA: a randomized, double-blind, placebo-controlled Phase III study with pertuzumab (P), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive first-line (1L) metastatic breast cancer (MBC) (2012) (21)
- Delphi‐panel analysis of appropriateness of high‐dose chemotherapy and blood cell or bone marrow autotransplants in women with breast cancer (2000) (21)
- Pharmacogenetics in Practice: Estimating the Clinical Actionability of Pharmacogenetic Testing in Perioperative and Ambulatory Settings (2020) (21)
- Chemotherapy: updates and new perspectives. (2010) (21)
- Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC). (2020) (20)
- Assessment of diagnosis of inflammatory breast cancer cases at two cancer centers in Egypt and Tunisia (2013) (20)
- Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: 5-year outcomes of NSABP protocol B-41. (2016) (19)
- Cardiac function in BRCA1/2 mutation carriers with history of breast cancer treated with anthracyclines (2016) (19)
- A critical review of the enrollment of black patients in cancer clinical trials. (2012) (19)
- UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation (2021) (19)
- Report on the International Colloquium on Cardio-Oncology (Rome, 12–14 March 2014) (2014) (19)
- Quality of life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. (2012) (19)
- Ixabepilone: clinical role in metastatic breast cancer. (2011) (18)
- A phase II trial of paclitaxel (Taxol®) as first line treatment in advanced breast cancer (2004) (18)
- Abstract S3-02: NSABP B-36: A randomized phase III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC) in patients (pts) with node-negative breast cancer (2015) (18)
- Tamoxifen and contralateral breast cancer: the other side. (2001) (18)
- Pertuzumab for the treatment of breast cancer: a safety review (2016) (18)
- Adverse events with pertuzumab and trastuzumab: Evolution during treatment with and without docetaxel in CLEOPATRA. (2012) (17)
- Does CDKN2A loss predict palbociclib benefit? (2015) (17)
- A Novel Case of Bisphosphonate-Related Osteonecrosis of the Torus Palatinus in a Patient with Metastatic Breast Cancer (2007) (17)
- A pilot study to evaluate response and angiogenesis after treatment with bevacizumab in patients with inflammatory breast cancer. (2004) (17)
- Ductal carcinoma in situ. (1992) (16)
- Amenorrhea in premenopausal women on the doxorubicin (A) and cyclophosphamide (C) → docetaxel (T) arm of NSABP B-30: Preliminary results (2005) (16)
- Assessment of primary care practitioners' attitudes and interest in pharmacogenomic testing. (2020) (15)
- Evaluation of lymphangiogenic factors, vascular endothelial growth factor D and E-cadherin in distinguishing inflammatory from locally advanced breast cancer. (2012) (15)
- Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in the CLEOPATRA study. (2012) (15)
- Pertuzumab for the Treatment of Breast Cancer (2014) (15)
- Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs (2019) (15)
- The role of primary chemotherapy in early breast cancer. (1996) (14)
- Treatment of HER2-positive metastatic breast cancer. (2015) (14)
- HALT‐D: A Phase II Evaluation of Crofelemer for the Prevention and Prophylaxis of Diarrhea in Patients With Breast Cancer on Pertuzumab‐Based Regimens (2017) (14)
- Video intervention increases participation of black breast cancer patients in therapeutic trials (2017) (14)
- Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study (2014) (14)
- Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab. (2016) (14)
- S5-5: A Phase III, Randomized, Double-Blind, Placebo-Controlled Registration Trial To Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Patients with Previously Untreated HER2−Positive Metastatic Breast Cancer (CLEOPATRA). (2011) (14)
- The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl (2016) (14)
- p53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer. (2011) (14)
- Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway (2020) (13)
- Breast Cancer Index (BCI) and prediction of benefit from extended aromatase inhibitor (AI) therapy (tx) in HR+ breast cancer: NRG oncology/NSABP B-42. (2021) (13)
- Pertuzumab: evolving therapeutic strategies in the management of HER2-overexpressing breast cancer (2013) (13)
- Pazopanib for the treatment of breast cancer (2012) (13)
- The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. (2011) (13)
- Hormone replacement therapy in women with a history of breast carcinoma. (1994) (12)
- Targeting HER2-positive breast cancer: advances and future directions (2022) (12)
- De Novo Versus Recurrent HER2‐Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry (2019) (12)
- Emerging drugs to replace current leaders in first-line therapy for breast cancer (2006) (12)
- Abstract 2837: A surrogate gene expression signature of tumor infiltrating lymphocytes (TILs) predicts degree of benefit from trastuzumab added to standard adjuvant chemotherapy in NSABP (NRG) trial B-31 for HER2+ breast cancer (2015) (12)
- NSABP B-38: Definitive analysis of a randomized adjuvant trial comparing dose-dense (DD) AC->paclitaxel (P) plus gemcitabine (G) with DD AC->P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer. (2012) (11)
- Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: The Phase III KAITLIN Study (2021) (11)
- Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 4: Urogenital atrophy, vasomotor instability, sleep disorders, and related symptoms. (1999) (11)
- Tumor markers: should we or shouldn't we? (2001) (11)
- Phase I trial of pentosan polysulfate (2007) (11)
- Improving Documentation of Pain Management at MedStar Washington Cancer Institute. (2015) (11)
- Effect of docetaxel duration on clinical outcomes: exploratory analysis of CLEOPATRA, a phase III randomized controlled trial (2017) (11)
- Ixabepilone for the treatment of solid tumors: a review of clinical data (2008) (10)
- Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function (2021) (10)
- Abstract PD2-1: The effect on overall and disease-free survival (OS & DFS) by adding bevacizumab and/or antimetabolites to standard neoadjuvant chemotherapy: NSABP Protocol B-40 (2015) (10)
- Systemic therapy of locally advanced breast cancer: review and guidelines. (1989) (10)
- Noninvasive breast cancer: Part 1. Ductal carcinoma in situ--incidence, presentation, guidelines to treatment. (1989) (10)
- Phase I trial of dasatinib and ixabepilone in patients with solid tumors (2013) (10)
- Abstract P5-18-01: Pertuzumab (P) in combination with trastuzumab (T) and docetaxel (D) in elderly patients with HER2-positive metastatic breast cancer in the CLEOPATRA study (2012) (10)
- A phase 2 trial of BMS-247550 (ixabepilone), an epothilone B analog, given daily x 5 in breast cancer. (2004) (10)
- Abstract P5-18-11: Pharmacokinetics and exposure-efficacy relationship of trastuzumab emtansine in EMILIA, a phase 3 study of trastuzumab emtansine vs capecitabine and lapatinib in HER2-positive locally advanced or metastatic breast cancer (2012) (10)
- The heart of the matter. (2007) (10)
- The tumor immune microenvironment of primary and metastatic HER2− positive breast cancers utilizing gene expression and spatial proteomic profiling (2021) (10)
- Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials (2020) (10)
- Concepts and clinical trials of dose-dense chemotherapy for breast cancer . (2005) (9)
- Molecular characterization of trophoblast cell surface antigen 2 (Trop-2) positive triple negative breast cancer (TNBC). (2019) (9)
- P1-07-02: Discordance between Central and Local Laboratory HER2 Testing from a Large HER2−Negative Population in VIRGO, a Metastatic Breast Cancer Registry. (2011) (9)
- NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response (2020) (9)
- Clinico-pathologic and mammographic characteristics of inflammatory and non-inflammatory breast cancer at six centers in North Africa (2019) (9)
- In situ or localized breast cancer--how much treatment is needed? (1993) (9)
- Exposure–safety relationship of trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer (MBC). (2013) (9)
- Breast cancer, locally advanced and metastatic (2012) (9)
- Abstract P3-07-14: Increasing proportion of de novo compared with recurrent HER2-positive metastatic breast cancer: Early results from the systemic therapies for HER2-positive metastatic breast cancer registry study (2015) (8)
- Utility of the 70-gene MammaPrint assay for prediction of benefit from extended letrozole therapy (ELT) in the NRG Oncology/NSABP B-42 trial. (2021) (8)
- Prevalence of Phosphatidylinositol-3-Kinase (PI3K) Pathway Alterations and Co-alteration of Other Molecular Markers in Breast Cancer (2020) (8)
- Chemotherapy: updates and new perspectives. (2010) (8)
- Therapy off patients with metastatic breast cancer with 5‐fluorouracil, leucovorin and carboplatin (1992) (8)
- SAFE-HEaRt: A pilot study assessing the cardiac safety of HER2 targeted therapy in patients with HER2 positive breast cancer and reduced left ventricular function. (2018) (8)
- Abstract PD6-03: Distribution of microsatellite instability, tumor mutational load, and PD-L1 status in molecularly profiled invasive breast cancer (2018) (8)
- Ixabepilone for the treatment of solid tumors: a review of clinical data. (2008) (8)
- The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40 (2017) (8)
- Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer (2021) (8)
- Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 2: Hormone replacement therapy and breast cancer. (1999) (8)
- Exposure–efficacy relationship of trastuzumab emtansine (T-DM1) in EMILIA, a phase III study of T-DM1 versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC). (2013) (8)
- Abstract S5-08: Late side-effects of breast cancer radiotherapy: Second cancer incidence and non-breast-cancer mortality among 40,000 women in 75 trials (2016) (8)
- Efficacy, safety and tolerability of dual monoclonal antibody therapy with pertuzumab + trastuzumab in HER2+ metastatic breast cancer patients previously treated with trastuzumab. (2009) (8)
- Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 6: Executive summary and consensus statement. Proceedings of a conference held at Boar's Head Inn, Charlottesville, Virginia, September 21-23, 1997. (1999) (8)
- IMpassion132: A double-blind randomized phase 3 trial evaluating chemotherapy (CT) ± atezolizumab (atezo) for early progressing locally advanced/metastatic triple-negative breast cancer (mTNBC). (2018) (7)
- Oophorectomy in carriers of BRCA mutations [3] (2002) (7)
- Lessons learned from the development of the CancerLinQ prototype: Clinical decision support. (2013) (7)
- Cardiac Protection in HER2-Targeted Treatment: How Should We Measure New Strategies? (2016) (7)
- Adjuvant therapy in early breast cancer. (1991) (7)
- Genomic profiling of breast cancer in African-American women using MammaPrint (2016) (7)
- Adjuvant trastuzumab: does time really matter? (2013) (6)
- Hormonal manipulation in the adjuvant treatment of breast cancer. (1993) (6)
- Efficacy of trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (MBC) previously treated with pertuzumab (P). (2017) (6)
- Contralateral breast cancer: where does it all begin? (2005) (6)
- Heparin‐Binding Growth Factor Blockade with Pentosan Polysulfate (1993) (6)
- Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials (2020) (6)
- Locally advanced breast cancer. (1989) (6)
- NSABP B-47: A randomized phase III trial of adjuvant therapy comparing chemotherapy alone to chemotherapy plus trastuzumab in women with node-positive or high-risk node-negative HER2-low invasive breast cancer. (2013) (6)
- Novel agents: clinical trial design. (2001) (6)
- Cardiotoxicity after doxorubicin and AZD2171, an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor, in patients (pts) with breast cancer (2007) (5)
- NSABP B-30: definitive analysis of quality of life (QOL) and menstrual history (MH) outcomes from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer. (2009) (5)
- Phase II clinical trial of ixabepilone in metastatic breast cancer (MBC) patients previously untreated with taxanes. (2006) (5)
- Risk factors for inflammatory and non-inflammatory breast cancer in North Africa (2020) (5)
- Skin and subcutaneous tissue disorders (SSTDs) in patients (pts) with HER2-positive metastatic breast cancer (MBC) in the phase III trial CLEOPATRA of pertuzumab or placebo with trastuzumab and docetaxel. (2015) (5)
- Intrinsic subtypes of HER2-positive breast cancer and their associations with pathologic complete response (pCR) and outcomes: Findings from NSABP B-41, a randomized neoadjuvant trial. (2018) (5)
- Reimbursement for solid tumor autologous bone marrow transplantation trials: a strategy for ensuring continuation of a promising therapy. (1991) (5)
- Multisite evaluation of institutional processes and implementation determinants for pharmacogenetic testing to guide antidepressant therapy (2021) (5)
- PD07-08: The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy: NSABP Protocol B-40. (2011) (5)
- 43O Pertuzumab/trastuzumab in early stage HER2-positive breast cancer: 5-year and final analysis of the BERENICE trial (2021) (5)
- Treatment and cost implications of pertuzumab. (2012) (4)
- BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer (2022) (4)
- A report of cardiac events in a phase II clinical study using trastuzumab combined with pertuzumab in HER2-positive metastatic breast cancer (MBC) (2007) (4)
- Inflammatory breast cancer. (2005) (4)
- Abstract GS2-04: Improvements in long-term outcome for women with estrogen receptor positive (ER+) early stage breast cancer treated with 5 years of endocrine therapy: Analyses of 82,598 women in the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) database (2020) (4)
- Bevacizumab beginning concurrently with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy followed by postoperative bevacizumab alone for women with HER2-negative locally advanced breast cancer (LABC): A phase II trial of the NSABP (2009) (4)
- Rationale and clinical trial design for evaluating gemcitabine as neoadjuvant and adjuvant therapy for breast cancer. (2004) (4)
- Pharmacokinetics (PK) of Pertuzumab (P) With Trastuzumab (T) and Docetaxel (D) in HER2-Positive First-Line Metastatic Breast Cancer (MBC): Results From the Phase III Trial Cleopatra (2012) (4)
- Effect of docetaxel duration on clinical outcomes: exploratory analysis of CLEOPATRA, a phase III randomized controlled trial. (2017) (4)
- The treatment of metastatic breast cancer with 5-fluorouracil and leucovorin. (1988) (4)
- Take care of your neighborhood (2017) (4)
- Locally advanced noninflammatory breast cancer. (1999) (4)
- Actionable coalterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway. (2019) (4)
- A pilot study to evaluate the vascular endothelial growth factor receptor tyrosine kinase inhibitor AZD2171 and chemotherapy in locally advanced and inflammatory breast cancer. (2005) (4)
- NRG Oncology/NSABP B-31: Stromal tumor infiltrating lymphocytes (sTILs) and outcomes in early-stage HER2-positive breast cancer (BC). (2018) (4)
- Mistletoe extract/gemcitabine combination treatment: An interim report from the NCCAM/NCI phase I study in patients with advanced solid tumors (2005) (4)
- Abstract GS2-06: Taxane with anthracycline versus taxane without anthracycline: An individual patient-level meta-analysis of 16,500 women with early-stage breast cancer in 13 randomised trials (2022) (4)
- Abstract PD8-04: Racial differences in the molecular landscape of breast cancer (2017) (3)
- Abstract P1-18-01: Risk of recurrence and death in patients with early HER2-positive breast cancer who achieve a pathological complete response (pCR) after different types of HER2-targeted therapy: A retrospective exploratory analysis (2020) (3)
- Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry (2021) (3)
- Focus on You: Cancer clinical trials perspectives (2016) (3)
- Dynamic contrast enhanced MRI (DCE-MRI) as a potential predictor of clinical response in patients with inflammatory breast cancer (IBC) (2005) (3)
- The tumor immune microenvironment of primary and metastatic HER2− positive breast cancers utilizing gene expression and spatial proteomic profiling (2021) (3)
- Tamoxifen and fluoxymesterone versus tamoxifen and danazol in metastatic breast cancer — A randomized study (1988) (3)
- HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now (2021) (3)
- NSABP FB-6: Phase II trial of weekly paclitaxel (WP) and pazopanib following doxorubicin and cyclophosphamide (AC) as neoadjuvant therapy for HER2-negative locally advanced breast cancer (LABC). (2012) (3)
- Abstract OT3-04-01: Nivolumab or capecitabine or combination therapy as adjuvant therapy for triple negative breast cancer (TNBC) with residual disease following neoadjuvant chemotherapy: The OXEL study (2019) (3)
- Erratum to “NCCAM/NCI Phase 1 Study of Mistletoe Extract and Gemcitabine in Patients with Advanced Solid Tumors” (2014) (3)
- Abstract GS2-04: Aromatase inhibitors versus tamoxifen in pre-menopausal women with estrogen receptor positive early stage breast cancer treated with ovarian suppression: A patient level meta-analysis of 7,030 women in four randomised trials (2022) (3)
- Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab. (2019) (3)
- Use of letrozole after aromatase inhibitor-based therapy (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled phase 3 trial. (2018) (3)
- Abstract P4-21-41: Primary analysis of BERENICE: A phase II cardiac safety study of pertuzumab, trastuzumab, and neoadjuvant anthracycline-based chemotherapy in patients with locally advanced, inflammatory, or early-stage, unilateral, and invasive HER2-positive breast cancer (2017) (3)
- Evaluation of neuropathy in breast cancer patients treated with ixabepilone (2005) (3)
- Doxorubicin-induced cardiomyopathy (1999) (2)
- Abstract PD2-1: Body mass index at diagnosis and breast cancer survival prognosis among clinical trial populations: Results from NSABP B-30, B-31, B-34, and B-38 (2013) (2)
- Evaluation of E-cadherin expression and lymphatic involvement in inflammatory breast cancer (2006) (2)
- Cardiovascular complications of breast cancer therapy. (2008) (2)
- Abstract P5-08-08: Baseline (BL) characteristics, treatment (tx) patterns, and outcomes in patients with hormone receptor (HR)+ vs HR– HER2+ disease from the SystHERs registry (2017) (2)
- Mitoxantrone, 5-FU, and leucovorin in breast cancer. (1994) (2)
- Abstract P4-12-10: Safety of pertuzumab (P) with trastuzumab (T) and docetaxel (D) in patients (pts) from Asia with HER2-positive metastatic breast cancer (MBC): Results from the phase III trial CLEOPATRA (2013) (2)
- Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology) (2021) (2)
- REVIEW Ductal Carcinoma In Situ, Complexities and Challenges (2004) (2)
- Abstract P3-04-01: ESR1 mutations, ESR1 fusions and co-occurring alterations assessed in breast cancer tumors (2017) (2)
- Indications for Neoadjuvant Therapy in Breast Cancer (2004) (2)
- First, Do no Harm (2008) (2)
- Concordance between independently and investigator-assessed progression-free survival in CLEOPATRA. (2012) (2)
- Enhanced Cardiac Testing in a Dual Anti-HER2 Regimen: What Have We Learned? (2016) (2)
- Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis (2022) (2)
- Effect of extended adjuvant endocrine therapy with letrozole (L) in postmenopausal women with hormone-receptor (+) breast cancer after prior adjuvant therapy with an aromatase inhibitor (AI): NRG Oncology/NSABP B-42 (2017) (2)
- Health policy: Upholding the Affordable Care Act—implications for oncology (2012) (2)
- Treatment of stage IIIA/B locally advanced breast cancer (LABC) with induction chemotherapy (CT) and hormonal synchronization (HS) followed by radiation therapy (RT) with or without mastectomy (1986) (2)
- A Passion for Solving the Puzzle of Cancer: Jane Cooke Wright, M.D., 1919-2013 (2013) (2)
- Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 1: Defining the problem. Proceedings of a conference held at the Boar's Head Inn Charlottesville, Virginia. September 21-23, 1997. (1999) (2)
- DPYD Testing: Time to Put Patient Safety First. (2023) (1)
- The Role of the Multidisciplinary Team in Inflammatory Breast Cancer (2012) (1)
- Meta-analysis: should it be more than the sum of its parts? (2010) (1)
- pAKT expression in paraffin-embedded xenograft tumors after fixation delays and human breast cancer by optimized immunohistochemistry. (2012) (1)
- Increasing participation in breast cancer research: (INSPIRE-BrC). (2014) (1)
- A clinical trial with culturally tailored video to increase participation of African Americans in cancer clinical trials. (2011) (1)
- Effect of bevacizumab (BV) and chemotherapy (CT) on serum levels of vascular endothelial growth factor receptor-2 (sVEGFR-2) in patients with inflammatory and locally advanced breast cancer. (2006) (1)
- Oophorectomy in carriers of BRCA mutations. (2002) (1)
- Abstract P4-14-27: Effect of docetaxel duration on clinical outcomes: Results from the phase III trial CLEOPATRA (2016) (1)
- HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane (2022) (1)
- Abstract P3-10-02: Increasing participation in research - breast cancer (Inspire-BrC) (2017) (1)
- Prognostic value of lymphocyte vascular density and e-cadherin in inflammatory breast cancer (2014) (1)
- Reply to a. Avan et Al. (2015) (1)
- Locally Advanced Breast Cancer: The National Cancer Institute Experience (1991) (1)
- A clinical trial with culturally appropriate video to increase participation of African Americans in cancer clinical trials. (2011) (1)
- Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 3: Prevention of osteoporosis and CV effects of estrogens and antiestrogens. (1999) (1)
- Controversies in the treatment of cancer of the breast. (1987) (1)
- 42O Biomarker analysis from KAITLIN, a randomised phase III study of adjuvant trastuzumab emtansine (TDM-1; K) plus pertuzumab (P) versus trastuzumab (H) plus taxane (T) plus P after anthracyclines (AC) for high-risk HER2-positive early breast cancer (EBC) (2021) (1)
- Left Ventricular Ejection Fraction Monitoring Adherence Rates: Why So Low? (2018) (1)
- Molecular pathways and gene ontology categories in association with response to combination chemotherapy plus bevacizumab in inflammatory and locally advanced breast cancer (2007) (1)
- Triple-Negative Breast Cancer: One Size Does Not Fit All. (2021) (1)
- A phase I study of the CDK4/6 inhibitor, palbociclib plus 5-fluorouracil (5FU) in patients with advanced solid tumor malignancies (NCT01522989). (2016) (1)
- Trends in the use of adjuvant therapy for women with breast cancer under age 65. (2015) (1)
- Abstract P6-17-01: Central nervous system metastases at diagnosis in patients with HER2+ MBC: Baseline characteristics, HER2-targeted treatments and clinical outcomes from the SystHERs registry (2016) (1)
- The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group (2021) (1)
- Genomic evaluation of tumor mutational burden-high (TMB-H) versus TMB-low (TMB-L) metastatic breast cancer to reveal unique mutational features. (2021) (1)
- Genomic profiling of breast cancer in African American women. (2013) (1)
- Guidelines for Long-Term Steroid Therapy in End-of-Life Palliative Care (2014) (1)
- Triple-negative breast cancer at Washington Cancer Institute (WCI) (2008) (1)
- Treatment of stage III breast cancer (1989) (1)
- Bevacizumab and Angiogenesis Inhibitors in the Treatment of CNS metastases: the Road less Travelled. (2013) (1)
- Insights from the cancer center business summit: preparing for the future. Foreword. (2013) (1)
- Reply to the Letter to the Editor from Jubb (2009) (1)
- Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831 (2020) (1)
- CardiacToxicity and Efficacy of Trastuzumab Combined with Pertuzumab in Patients with Trastuzumab-Insensitive Human Epidermal Growth Factor Receptor 2^ Positive Metastatic Breast Cancer (2008) (0)
- Trastuzumab-based regimens beyond progression: A crucial treatment option for HER2+ advanced/metastatic breast cancer (2022) (0)
- Abstract P5-08-27: Treatment patterns and clinical outcomes in patients with hormone receptor (HR)+ HER2+ metastatic breast cancer and low vs high levels of HR positivity from the SystHERs Registry (2017) (0)
- Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41. (2023) (0)
- TREATMENT OF CANCER OF THE BREASTl (1987) (0)
- Abstract 2718: Digital spatial profiling in HER2 positive breast cancer: The road to precision medicine (2021) (0)
- Approach of Locally Advanced Nonmetastatic Breast Cancer Neoadjuvant Chemotherapy in the Combined Modality (2006) (0)
- Effect of bevacizumab and chemotherapy on serum levels of sVCAM-1 in patient with inflammatory and locally advanced breast cancer (2005) (0)
- Molecular characterization of ESR1 variants in breast cancer (2022) (0)
- Panel Discussion II (1987) (0)
- Abstract P4-09-04: Prevalence of phosphatidylinositol-3-kinase (PI3K) pathway alterations and co-alteration of other markers in breast cancer (2020) (0)
- Pertuzumab: increasing the options. (2014) (0)
- Diarrhea prevention and prophylaxis with crofelemer in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and docetaxel or paclitaxel with or without carboplatin. (2016) (0)
- Determining the rate of tumor growth and decay in patients with metastatic breast cancer as an early efficacy endpoint: A study assessing ixabepilone efficacy. (2011) (0)
- Abstract 532: Association of pCR and the 8-gene signature: NRG Oncology/NSABP B-41 (2021) (0)
- Abstract P5-18-09: Halt-d: A randomized open label phase 2 study of crofelemer for the prevention of chemotherapy induced diarrhea (cid) in patients with breast cancer receiving trastuzumab, pertuzumab, and a taxane (2022) (0)
- Results From the Phase III Trial CLEOPATRA Asia With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Safety Profile of Pertuzumab With Trastuzumab and Docetaxel in Patients From (2014) (0)
- Abstract P5-17-01: A definition of a high-risk early-breast cancer population based on data from the collaborative trials in neoadjuvant breast cancer (CTNeoBC) meta-analysis (2013) (0)
- Abstract A18: Increasing Participation in Research - Breast Cancer (2015) (0)
- Abstract PD9-02: Peripheral immune subsets and circulating tumor DNA (ctDNA) in patients (pts) with residual triple negative breast cancer (TNBC) treated with adjuvant immunotherapy and/or chemotherapy (chemo): The OXEL study (2022) (0)
- Abstract 123: Multiplatform molecular profiling of invasive lobular breast cancer (2016) (0)
- Can we increase survival in breast cancer with innovative applications of conventional drugs? (1994) (0)
- 5025 POSTER DISCUSSION Phase 3 Study of Iniparib (I) Plus Gemcitabine (G) and Carboplatin (C) in Metastatic Triple-negative Breast Cancer (mTNBC) – Results of an Exploratory Analysis by Prior Therapy (2011) (0)
- Video intervention increases participation of black breast cancer patients in therapeutic trials (2017) (0)
- Abstract OT3-03-01: Increasing participation in research - Breast cancer: (2016) (0)
- Abstract C24: Phase I trial of dasatinib and ixabepilone in patients with solid tumors. (2011) (0)
- Breast cancer at the millennium: the new frontier. (2001) (0)
- 138P Anaphylaxis and hypersensitivity in trials of intravenous pertuzumab + trastuzumab (PH IV) or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) for HER2-positive breast cancer (BC) (2021) (0)
- Physician roundtable: Does screening lead to overdiagnosis? (2013) (0)
- Potential and Pitfalls of Pharmacovigilance Databases in Oncology (2023) (0)
- Best–worst scaling methodology to evaluate constructs of the Consolidated Framework for Implementation Research: application to the implementation of pharmacogenetic testing for antidepressant therapy (2022) (0)
- Abstract P4-09-05: Somatic genomic profiles of breast tumors differ byBRCA1andBRCA2variants of unknown significance status (2020) (0)
- Cultural competency training for health care providers in an urban cancer institute and impact on breast care. (2013) (0)
- NSABP B-41, a randomized neoadjuvant trial: Genes and signatures associated with pathologic complete response (pCR). (2019) (0)
- Prognostic and predictive implications of the intrinsic subtypes and gene expression signatures in early-stage HER2+ breast cancer: A pooled analysis of CALGB 40601, NeoALTTO, and NSABP B-41 trials. (2022) (0)
- OR048 The effect of multidisciplinary asthma clinic on high-risk patients (2017) (0)
- Abstract PD14-08: Effectiveness of aromatase inhibitors versus tamoxifen in lobular compared to ductal carcinoma: Individual patient data meta-analysis of 9328 women with central histopathology, and 7654 women with e-Cadherin status (2022) (0)
- HER2-Neu in Breast Cancer: History and Future Directions (2012) (0)
- CURRENT STANDARD OF CARE FOR HER2+ ABC (2021) (0)
- Erratum: NCCAM/NCI Phase 1 Study of Mistletoe Extract and Gemcitabine in Patients with Advanced Solid Tumors (Evidence-based Complementary and Alternative Medicine) (2014) (0)
- IN03 IS THERE AN OPTIMAL TREATMENT SEQUENCE FOR HER2 POSITIVE ADVANCED BREAST CANCER (2015) (0)
- 274PBaseline characteristics and first-line (1L) treatment of patients with HER2+ metastatic breast cancer (MBC) from the SystHERs registry (2017) (0)
- Post-CDK 4/6 Inhibitor Therapy: Current Agents and Novel Targets (2023) (0)
- HER2 alterations and prognostic implications in all subtypes of breast cancer. (2022) (0)
- Abstract OT1-1-12: SAFE-HEaRt: A pilot study assessing the cardiac SAFEty of HER2 targeted therapy in patients with HER2 positive breast cancer and reduced left ventricular function (2013) (0)
- Abstract P1-07-04: Potential role of the antibody-dependent cellular phagocytosis (ADCP) in tumors achieving pCR in NRG Oncology/NSABP B-52 (2022) (0)
- Drug discount program. (2013) (0)
- Abstract P5-21-01: Effect of adjuvant systemic therapy in reducing rates of loco-regional recurrence in early-stage breast cancer: Results from nine NSABP randomized phase III trials (2015) (0)
- Magnitude of Estrogen Deficiency Problem in Breast Cancer Survivors (1998) (0)
- Abstract of ASTRO scientific papers to be presentedThe effect of systemic therapy upon local-regional control in locally adbanced breast cancer (1991) (0)
- Defining the IBC Phenotype (2008) (0)
- Abstract P1-03-01: Cardiac function in BRCA1/2 mutation carriers with a history of breast cancer (BC) treated with anthracyclines (anthra) (2015) (0)
- Abstract OT-26-03: Racial disparities inCYP3Avariants in the metabolism of ribociclib in breast cancer patients (2021) (0)
- Early assessment of efficacy of ixabepilone (IXA) by analysis of the rate of tumor growth and decay using data from phase II and phase III clinical trials in metastatic breast cancer (MBC) patients (Pts). (2011) (0)
- Building bridges to conquer cancer. (2013) (0)
- 275PFirst-line treatment patterns by age for patients (pts) with HER2+ metastatic breast cancer (MBC) in the SystHERs registry (2017) (0)
- Abstract P5-20-04: Safety of adjuvant treatment with pertuzumab plus trastuzumab after neoadjuvant anthracycline-based chemotherapy in patients with HER2-positive localized breast cancer: Updated results from the BERENICE study (2018) (0)
- Multimodality treatment of stage II, III and IV breast cancer with biochemical modulation of 5-FU/Leucovorin and estrogen recruitment (1991) (0)
- Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function. (2020) (0)
- HER 2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer (0)
- Noninvasive breast cancer: Part 2. Lobular carcinoma in situ--incidence, presentation, guidelines to treatment. (1989) (0)
- Issue Information (2022) (0)
- Salvage Treatment with Intermediate‐Dose Methotrexate and 5‐Fluorouracil in Metastatic Breast Cancer (1988) (0)
- Oncotype DX Recurrence Score and treatment choices according to ethnicity. (2016) (0)
- P1578Global longitudinal strain in the SAFE-HEaRT study (Cardiac SAFEty of HER2 targeted therapy in patients with HER2 positive breast cancer and reduced left ventricular function) (2018) (0)
- Experience and impact of alopecia in patients (pts) with HER2+ metastatic breast cancer (MBC) in the SystHERs registry. (2017) (0)
- First , Do no Harm Filipa Lynce (2008) (0)
- Abstract P2-11-07: Association of PIK3CA mutations with efficacy in HER2-positive first-line metastatic breast cancer: a meta-analysis (2023) (0)
- Clinical trials decision-making in African American patients with cancer: The role of cancer-coping religious beliefs. (2012) (0)
- Clinical breast cancer research core (2004) (0)
- Abstract CT129: Association of the FCGR2A and FCGR3A genotypes with trastuzumab benefit in NSABP B-31 (2015) (0)
- The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer (2014) (0)
- Correction to: Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology) (2022) (0)
- A phase II clinical trial of ZD1839 (gefitinib) in combination with docetaxel as first-line treatment in patients with advanced breast cancer (2007) (0)
- Elevated levels of eukaryotic initiation factor 4E correlate with VEGF, cyclin D1 and c-myc expression in multi-tumor tissue microarray (2003) (0)
- Management of HER2-Positive Metastatic Breast Cancer: Standard and New Approaches (2010) (0)
- Abstract PD15-05: Assessment of estrogen receptor (ESR1) mRNA expression for prediction of extended aromatase inhibitor benefit in HR-positive breast cancer using NRG Oncology/NSABP B-42 (2022) (0)
- Could Some Reports of Trastuzumab Cardiotoxicity Be a Surveillance Artifact? (2022) (0)
- Chemotherapy induced amenorrhea as an indicator of better survival in early breast cancer (2010) (0)
- Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer. (2022) (0)
- Abstract P5-10-05: TRAIL receptor agonists target basal B triple negative breast Cancer (TNBC) that expresses vimentin and axl (2015) (0)
- Avastin withdrawal symptoms (2012) (0)
- AJ. drug development and biomarker (2012) (0)
- Screening for breast cancer and adjuvant therapy for early breast cancer. (1989) (0)
- Abstract A15: Increasing participation in therapeutic clinical trials among African Americans with cancer (2010) (0)
- Current Management of Menopausal Symptoms in Cancer Patients (2002) (0)
- A randomized trial of five years of letrozole versus placebo after aromatase inhibitor-based therapy: NRG Oncology/NSABP B-42 (2019) (0)
- Abstract OT3-1-01: A two-cohort, phase II, cardiac safety study of pertuzumab, trastuzumab, and neoadjuvant anthracycline-based chemotherapy in patients with HER2-positive, locally advanced, inflammatory, or early breast cancer (2015) (0)
- A phase I study of ixabepilone combined with dasatinib in patients with solid tumors. (2010) (0)
- Reply to E.J. Moylan et al. (2014) (0)
- A step in the right direction (2006) (0)
This paper list is powered by the following services:
Other Resources About Sandra M. Swain
What Schools Are Affiliated With Sandra M. Swain?
Sandra M. Swain is affiliated with the following schools:
- University of Texas at Austin
- University of Kentucky
- MD Anderson Cancer Center
- University of Oxford
- University of Michigan
- Baylor University
- Uniformed Services University of the Health Sciences
- Yale University
- Stanford University
- Georgetown University
- University of Tübingen
- University of Pittsburgh
- University of North Carolina at Chapel Hill
- University of Florida College of Medicine
